BiogenedWAR:BGD 68 Forward Dividend Yield % is 2.72% as of Jul. 03, 2026. GuruFocus rates WAR:BGD with a GF Score™ of 68/100 and a GF Value™ of zł23.81 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 506 Drug Manufacturers companies, Biogened ranks better than 61.46% on this metric.
As of today (2026-07-03), the Forward Annual Dividend Yield of Biogened is 2.72%.
As of today (2026-07-03), the Trailing Annual Dividend Yield of Biogened is 2.72%.
WAR:BGD's Forward Dividend Yield % is ranked better than 61.46% of 506
companies
in the Drug Manufacturers industry
Industry Median: 2.03
vs WAR:BGD: 2.72
During the past 3 years, the average Dividends Per Share Growth Rate was 18.60% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 24.30% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Biogened was 35.70% per year. The lowest was 18.60% per year. And the median was 26.00% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
WAR:BGD vs ZTS, UTHR, VTRS: Forward Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biogened's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogened Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biogened's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Biogened's Forward Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Biogened Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
PLN 0.500000
2025-09-11
2025-09-12
2025-11-17
Cash Dividend
annually
PLN:PLN 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Biogened's Forward Annual Dividend Yield (%) for Today is calculated as
Forward Annual Dividend Yield
=
Forward Full Year Dividend
/
Current Share Price
=
0.5
/
18.40
=
2.72 %
Current Share Price is zł18.40. Biogened's Dividends per Share for the forward twelve months is calculated as zł0.5 * 1 = zł0.5.
Biogened's Trailing Annual Dividend Yield (%) for Today is calculated as
Trailing Annual Dividend Yield
=
Most Recent Full Year Dividend
/
Current Share Price
=
0.5
/
18.40
=
2.72 %
Current Share Price is zł18.40. Biogened's Dividends per Share for the trailing twelve months (TTM) ended in Today is zł0.5.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Forward Dividend Yield % of 2.72% mean?
Biogened (WAR:BGD) has a Forward Dividend Yield % of 2.72% as of Jul. 03, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Biogened and its competitors. According to the industry distribution chart, Biogened ranks #195 out of 506 companies in the Drug Manufacturers industry, placing it in the top 38.5%.
Is Biogened's Forward Dividend Yield % too high?
Biogened's current Forward Dividend Yield % is 2.72%. The Drug Manufacturers industry median Forward Dividend Yield % is 2.03. Biogened's value of 2.72% is 34% above this industry median. Based on the distribution chart, Biogened ranks #195 out of 506 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Biogened has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biogened's Forward Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biogened ranks #195 out of 506 companies for Forward Dividend Yield %. This puts Biogened in the upper half of its industry. The industry median Forward Dividend Yield % is 2.03. Biogened's value of 2.72% is 34% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.03, based on 506 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biogened's current Forward Dividend Yield % of 2.72% is 34% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Biogened and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biogened's current Forward Dividend Yield % is 2.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogened stock overvalued right now?
Based on GuruFocus' analysis, Biogened (WAR:BGD) is currently considered Modestly Undervalued. The stock's GF Value™ is zł23.81, compared to a current price of zł18.40 — trading 22.7% below its estimated fair value. The current Forward Dividend Yield % is 2.72% and 34% above the Drug Manufacturers industry median of 2.03. Biogened's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Biogened (WAR:BGD), the current Forward Dividend Yield % is 2.72% as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biogened (WAR:BGD) Overvalued in 2026?
Based on GuruFocus' analysis, Biogened stock appears to be undervalued.
The current stock price of zł18.40 is trading 22.7% below its estimated GF Value™ of zł23.81.
GuruFocus considers Biogened to be Modestly Undervalued.
Key valuation signals for WAR:BGD:
Forward Dividend Yield %: 2.72%
GF Value™: zł23.81 vs. price of zł18.40 (22.7% below fair value)
Industry Position: 34% above the Drug Manufacturers median (#195 of 506)
No single metric tells the full story. See the WAR:BGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biogened SA is involved in manufacturing cosmetic and hygiene products. It also designs, produces, and markets safe, effective dermo-cosmetics under the Dermedic brand. The company's products include Dermocosmetics, Thermal water, and Pharmaceutical manufacturing conditions.
68GF Score
Get the complete analysis for WAR:BGD
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:BGD has been successfully added to your 